Vitruvias Therapeutics, Inc.
NDC labeler code: 69680
What is a labeler?
The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.
Official FDA data only
Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.
Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.
Prescription medicines
- TopiramateTopamax, Qudexy XR, Trokendi XR · 5 products
- Memantine hydrochloride4 products
- Memantine and donepezilMemantine and Donepezil Hydrochlorides Extended-Release, Namzaric · 2 products
- Pramipexole dihydrochloride2 products
- Icosapent ethylVascepa · 1 product
FDA applications for these products
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Approved | Application | Medicine | Sponsor |
|---|---|---|---|
| August 6, 2025 | ANDA219156 | Icosapent ethyl ICOSAPENT ETHYL | Xiamen LP Pharm Co |
| July 15, 2025 | ANDA216901 | Memantine and donepezil MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE | Xiamen LP Pharm Co |
| November 5, 2024 | ANDA215638 | Topiramate TOPIRAMATE | Xiamen LP Pharm Co |
| October 11, 2022 | ANDA213985 | Memantine hydrochloride MEMANTINE HYDROCHLORIDE | H2-Pharma |
| June 11, 2021 | ANDA212797 | Pramipexole dihydrochloride PRAMIPEXOLE DIHYDROCHLORIDE | Xiamen LP Pharm Co |
The sponsor is the company that holds the FDA application; it can differ from the labeler.
Recall timeline
2021
-
March 15, 2021 · Class II · Terminated · D-0595-2021 · Cyanocobalamin
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
CYANOCOBAL Injection 1000MCG/ML 25X1ML; NDC/UPC 69680-112-25; RX; MULTI DOSE VIAL
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Next steps
- Find a pharmacy near youAsk which company made your medicine and whether it is recalled
- Latest FDA drug recallsAll companies, newest first
- All drug companiesA to Z
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026